Acorda Therapeutics (ACOR) Tops Q2 EPS by 68c, Revenues Beat; Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Provides Financial and Pipeline Update for Second Quarter 2018
August 2, 2018 6:00 AM EDTINBRIJA (levodopa inhalation powder) NDA under FDA review; PDUFA date October 5, 2018 AMPYRA® (dalfampridine) 2Q 2018 net sales of $150.3 million; reiterating 2018 guidance of $330-$350 million Awaiting AMPYRA patent decision from U.S. Court of Appeals
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the quarter... More
